Open Access

Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer

  • Authors:
    • Rafał Stec
    • Aleksandra Semeniuk-Wojtaś
    • Radosław Charkiewicz
    • Lubomir Bodnar
    • Jan Korniluk
    • Marta Smoter
    • Lech Chyczewski
    • Jacek Nikliński
    • Cezary Szczylik
  • View Affiliations

  • Published online on: June 19, 2015     https://doi.org/10.3892/ol.2015.3398
  • Pages: 1423-1429
  • Copyright: © Stec et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC) is one of the most common cancers worldwide, with ~700,000 mortalities occurring due to CRC in 2012. The treatment options are effective in a small percentage of patients, and it is important to identify specific biomarkers in order to determine patients for whom the available therapies will be beneficial. It has been hypothesised that the PIK3CA gene mutation may affect the response to therapy of patients with metastatic CRC. In the present study, primary tumour specimens were collected from 156 patients with CRC who were treated in the Military Institute of Medicine in Warsaw (Warsaw, Poland). Codons 12 and 13 of exon 1 of KRAS, exons 11 and 15 of BRAF and exons 9 and 20 of PIK3CA were analysed for mutation using direct sequencing. The prognostic value of each mutation and the clinical and pathological variables of these tumours were estimated. The results revealed that PIK3CA mutations were present in 15 patients (9.6%), of whom seven (46.7%) possessed mutations in codon 9 and eight (53.3%) possessed mutations in codon 20. Mutation in the PIK3CA gene was detected in six patients with KRAS gene mutations, which accounted for 40% of PIK3CA‑mutated tumours, and in one patient with BRAF mutations, which accounted for 6.6% of PIK3CA‑mutated tumours. No significant differences were identified between the overall survival (OS) rates of patients with PIK3CA mutations (median OS, 56.7 months) and those with wild‑type PIK3CA genes (median OS, 47.6 months) (P=0.1270). Univariate analysis identified that the following prognostic factors affected the OS rate in the current patient cohort: Gender, female patients survived for 57.5 months compared with 39.3 months for male patients (P=0.0111); and lymph node involvement grade, as survival of patients without lymph node metastases was 61.4 months compared with 45.4 months in patients presenting with metastases (P=0.0122). The findings of the present analysis indicate that PIK3CA mutation status is not a prognostic factor in CRC patients. In addition, no statistically significant association exists between tumours with PIK3CA mutations and clinical or pathological factors.
View Figures
View References

Related Articles

Journal Cover

September-2015
Volume 10 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Stec R, Semeniuk-Wojtaś A, Charkiewicz R, Bodnar L, Korniluk J, Smoter M, Chyczewski L, Nikliński J and Szczylik C: Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer. Oncol Lett 10: 1423-1429, 2015.
APA
Stec, R., Semeniuk-Wojtaś, A., Charkiewicz, R., Bodnar, L., Korniluk, J., Smoter, M. ... Szczylik, C. (2015). Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer. Oncology Letters, 10, 1423-1429. https://doi.org/10.3892/ol.2015.3398
MLA
Stec, R., Semeniuk-Wojtaś, A., Charkiewicz, R., Bodnar, L., Korniluk, J., Smoter, M., Chyczewski, L., Nikliński, J., Szczylik, C."Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer". Oncology Letters 10.3 (2015): 1423-1429.
Chicago
Stec, R., Semeniuk-Wojtaś, A., Charkiewicz, R., Bodnar, L., Korniluk, J., Smoter, M., Chyczewski, L., Nikliński, J., Szczylik, C."Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer". Oncology Letters 10, no. 3 (2015): 1423-1429. https://doi.org/10.3892/ol.2015.3398